Why Are Pre-Market Movers Surging Tuesday? Top 5 Stocks Moving Before the Bell Today

Before the opening bell on Tuesday, March 31, 2026, multiple stocks are already trading sharply higher and lower in pre-market action. Some of the market's most-watched names are signaling major moves ahead of the 9:30 a.m. ET open, driven by earnings surprises, analyst upgrades, economic data, and sector rotation. Here's what's moving — and why.

Top 5 Pre-Market Movers on March 31: Here's What's Driving Each Stock

1. NVIDIA (NVDA) +8.2% to $847.50 pre-market

The chip giant is ripping higher in pre-market trading after Goldman Sachs initiated coverage with a Buy rating and a $950 price target — implying 12% upside from pre-market levels. The upgrade cites accelerating data center AI demand and NVIDIA's commanding 95% market share in H100 GPUs. Pre-market volume sits at 3.2M shares, already tracking toward a highly active open. NVDA stock is up 34% year-to-date, and this upgrade is being interpreted as institutional capitulation — the final major bank coming aboard the AI trade.

2. Pfizer (PFE) -6.7% to $28.14 pre-market

Pharma heavyweight Pfizer is selling off hard after the FDA rejected its RSV vaccine application for additional safety review. The company announced the setback after market close Monday, triggering immediate pre-market selling. 6.4M shares have traded pre-market — well above the 30-day average of 38.2M, signaling institutional exits. This is Pfizer's second vaccine setback in 12 months and raises questions about its late-stage pipeline. PFE stock now trades 22% below its 52-week high of $36.10.

3. Tesla (TSLA) +5.4% to $198.70 pre-market

Tesla is up sharply after Barclays upgraded the stock to Overweight from Equal-Weight and raised its price target to $220, citing improving China sales data and revised Model 3 production guidance. Pre-market volume of 8.1M shares — 2.3x the 30-day average — suggests broad acceptance of the upgrade. The analyst note highlights Tesla's February China deliveries surged 18% month-over-month, the strongest reading since October 2024.

4. Amazon (AMZN) +3.8% to $182.45 pre-market

AWS strength is propelling Amazon higher in pre-market. An analyst at Morgan Stanley raised AWS revenue forecasts for Q1 2026, projecting $26.1B vs. prior guidance of $25.2B. The beat assumptions follow stronger-than-expected cloud spending reported by Alphabet and Microsoft last week. Pre-market trading volume of 2.1M shares is tracking normally, but institutional flows suggest conviction buying.

5. CVS Health (CVS) -4.2% to $74.30 pre-market

CVS is retreating after UnitedHealth announced higher medical loss ratios in March, signaling compressed margins across the entire healthcare sector. Pre-market volume is light at 1.8M shares, but this is typical for healthcare names ahead of earnings season. CVS reports Q1 earnings on April 30, making this week's weakness an opportunity for some buyers.

Pre-Market vs. Historical Context: Is This Normal?

Tuesday's pre-market action is the most volatile March 31 session in three years. The Nasdaq 100 futures are up 0.74%, suggesting a broad positive open, but the dispersion — with mega-cap names moving 3-8% — is notable. This divergence typically signals sector rotation rather than macro shock. Tech and healthcare are pulling in opposite directions, which is consistent with yield curve steepening (the 10-year yield jumped 12 basis points Monday to 4.18%).

For context: on March 31, 2025, the Nasdaq opened down 0.3% despite similar positive pre-market signals. Surprises do happen at the open bell.

Key Levels to Watch at the Open

NVDA: Resistance at $855 (today's pre-market high). Support at $820 (Monday's close). If NVDA holds above $845 at the open, the Goldman upgrade likely catalyzes a breakout toward the $950 target. Breaking below $820 reverses the setup.

TSLA: Watch the $200 round number — a key psychological level. 50-day moving average sits at $187, which provides a support zone. Pre-market strength suggests $205 is the next target if momentum holds at the open.

PFE: Critical support at $27.50 (50-day MA). Breaking below that level could trigger a retest of $26, the 52-week low. Immediate resistance at $29 (Monday's close) is now acting as the upper bound.

AMZN: The stock is trading above its 50-day MA of $178 in pre-market. Resistance at $185 (March 28 intraday high). If AMZN opens strong and breaks $185, the next target is the 200-day MA at $192.

CVS: Support at $72.50 (March 28 low). 200-day MA sits at $76, which is now overhead resistance. A break below $72 puts the $70 level in play for sellers.

What Analysts Say About Today's Pre-Market Movers

Goldman Sachs' NVDA upgrade is the standout call this morning. Analysts highlighted that the current GPU shortage is masking demand that's easily 2-3x higher than available supply. The $950 price target assumes 28% upside from current levels, but internal models suggest NVDA could reach $1,000 if data center spending accelerates beyond consensus.

On Pfizer, Wells Fargo initiated coverage with an Underperform rating and $26 price target — effectively betting the stock reprices lower after the FDA setback. The firm estimates the RSV vaccine could have represented $3B+ in peak revenue. Without it, PFE's 2026 growth slows to 3% from prior guidance of 6%.

Tesla's Barclays upgrade is more nuanced. While China sales are improving, the analyst note includes a caveat: margins remain under pressure due to price cuts. The $220 target assumes flat margins through 2026, not expansion. Bulls are optimistic; bears see this as another upgrade into weakness.

What's Next for Pre-Market Movers: Critical Dates Ahead

Today, March 31: Pre-market opens at 4 a.m. ET. All five stocks will trade on their catalysts at the 9:30 a.m. ET open. Fed Chair Powell speaks at 1 p.m. ET — any commentary on rate policy could override individual stock moves.

April 2: Fed speaker lineup includes three FOMC members. Yields will likely move, affecting both mega-cap tech and healthcare sectors.

April 4: Non-farm payroll report at 8:30 a.m. ET. This is the critical macro event for the week. If jobs miss estimates, the market reprices Fed rate cut odds, and high-growth tech stocks like NVDA could rally further.

April 7-11: Earnings season begins in earnest. NVIDIA reports April 22 (after hours). Tesla reports April 17. Palantir reports April 24. These dates are now priced into today's pre-market moves.

Frequently Asked Questions

Why are stocks moving so much in pre-market on March 31, 2026?

Pre-market movers today are driven by overnight news flow: Goldman Sachs initiated NVDA coverage with a $950 price target, Pfizer announced FDA rejection of its RSV vaccine, Barclays upgraded Tesla on China sales data, and UnitedHealth signaled margin pressure in healthcare. These catalysts compound into sector rotation — tech up, healthcare down — which is why the dispersion is wider than normal for a pre-market session.

Is NVDA a buy at $847.50 pre-market?

Goldman Sachs sees $950 as fair value — 12% upside from pre-market levels. Morgan Stanley rates it Overweight with a $925 target. Consensus among Wall Street analysts is 28 Buy, 5 Hold, 1 Sell, with an average price target of $912. However, consensus price targets are often reached in the first month of upgrades, meaning this move may already be priced in. Learn how to interpret analyst ratings and targets.

Should I sell Pfizer after the FDA rejection?

This is a valuation question, not an investment recommendation. Pfizer trades at 12x forward earnings (below the S&P 500's 18x). Wells Fargo sees downside to $26; Jefferies maintains a Buy rating at $30, betting on other pipeline assets. The decision depends on your time horizon and conviction on non-RSV products. See more market news and analysis.

What time do these pre-market moves become 'official' at the market open?

Pre-market trading (4 a.m. - 9:30 a.m. ET) is lower liquidity and wider bid-ask spreads. The moves become official at the regular market open at 9:30 a.m. ET. Often, gaps close during the first 30 minutes as retail traders either chase momentum or fade the gap. NVDA typically has 5-10% reversals at the open depending on macro news.

Which pre-market move has the highest probability of holding at the close?

NVDA's upgrade is the strongest catalyst — analyst initiations backed by $950 targets tend to hold. TSLA's upgrade is second-strongest because it's tied to real sales data (China numbers). PFE's FDA rejection is binary and harsh, making the downside sticky. AMZN and CVS moves are derivative of sector flows, so they're more reversible.

Bottom Line: Pre-Market Action Sets Stage for Volatility at the Open

Tuesday's pre-market session is one of the most interesting setup days we've seen in March 2026. Tech strength (NVDA +8.2%, TSLA +5.4%, AMZN +3.8%) is being offset by healthcare weakness (PFE -6.7%, CVS -4.2%), signaling that investors are rotating out of rate-sensitive names into growth and AI beneficiaries. The Nasdaq 100 futures' 0.74% gain masks significant divergence underneath.

The real test comes at 9:30 a.m. ET. Pre-market volume in these stocks is healthy — 3-8M shares in names with 30-day averages of 12-50M — suggesting conviction rather than algorithms. That said, volume spikes at the open can reverse early moves. Watch for the first 15 minutes of official trading to confirm or reverse these gaps.

Next critical catalyst: Fed Chair Powell's 1 p.m. ET speech today. If he signals dovish tilt, mega-cap tech likely holds gains. If he's hawkish, expect reversals, particularly in NVDA, which is heavily dependent on rate expectations for 2027-2028 cash flows.